Salaheldin S Hamed

6PUBLICATIONS
71CO-AUTHORS
GlycoconjugatesCancer therapy (excl. chemotherapy and radiation therapy)Medical biotechnology not elsewhere classifiedPharmacogenomicsFlight dynamics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 06, 2026
Clinical Pharmacology and Translational Science Considerations in the Development of Dual-Payload Antibody Drug Conjugates.

|May 05, 2026
Enfortumab vedotin plus pembrolizumab as first-line treatment in recurrent or metastatic head and neck squamous cell carcinoma: results from EV-202 cohort 9.

|Aug 18, 2025
FDA Approval Summary: Nogapendekin Alfa Inbakicept-pmln with BCG for BCG-Unresponsive Carcinoma In Situ.

Brian L Heiss, Elaine Chang, Hee-Koung Joeng

|Jul 17, 2025
FDA Approval Summary: Niraparib plus Abiraterone Acetate Fixed-Dose Combination for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer.

William F Maguire, Dow-Chung Chi, Sundeep Agrawal

|Mar 05, 2024
FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Cisplatin-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma.

William F Maguire, Daniel Lee, Chana Weinstock

|May 22, 2023
FDA Approval Summary: Mirvetuximab Soravtansine-Gynx for FRα-Positive, Platinum-Resistant Ovarian Cancer.

Asma Dilawari, Mirat Shah, Gwynn Ison

Pageof 1

Frequent Collaborators

4 joint publications

Laleh Amiri-Kordestani

4 joint publications

Paul G Kluetz

4 joint publications

Shenghui Tang

3 joint publications

Richard Pazdur